Sridharan Raghavan1,2,3, Yuk-Lam Ho4, Vinay Kini3,5, Mary K Rhee6,7, Jason L Vassy4,8,9, David R Gagnon4,10, Kelly Cho4,8, Peter W F Wilson6,11, Lawrence S Phillips6,7. 1. Veterans Affairs Eastern Colorado Healthcare System, Aurora, CO sridharan.raghavan@ucdenver.edu. 2. Division of Hospital Medicine, University of Colorado School of Medicine, Aurora, CO. 3. Colorado Cardiovascular Outcomes Research Consortium, Aurora, CO. 4. Veterans Affairs Boston Healthcare System, Boston, MA. 5. Division of Cardiology, University of Colorado School of Medicine, Aurora, CO. 6. Atlanta Veterans Affairs Medical Center, Decatur, GA. 7. Division of Endocrinology, Metabolism, and Lipids, Emory University School of Medicine, Atlanta, GA. 8. Department of Medicine, Harvard Medical School, Boston, MA. 9. Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA. 10. Department of Biostatistics, Boston University School of Public Health, Boston, MA. 11. Division of Cardiology, Emory University School of Medicine, Atlanta, GA.
Abstract
OBJECTIVE: Guidelines for hypertension treatment in patients with diabetes diverge regarding the systolic blood pressure (SBP) threshold at which treatment should be initiated and treatment goal. We examined associations of early SBP treatment with atherosclerotic cardiovascular disease (ASCVD) events in U.S. adults with diabetes. RESEARCH DESIGN AND METHODS: We studied 43,986 patients with diabetes who newly initiated antihypertensive therapy between 2002 and 2007. Patients were classified into categories based on SBP at treatment initiation (130-139 or ≥140 mmHg) and after 2 years of treatment (100-119, 120-129, 130-139, 140-159, and ≥160 mmHg). The primary outcome was composite ASCVD events (fatal and nonfatal myocardial infarction and stroke), estimated using inverse probability of treatment-weighted Poisson regression and multivariable Cox proportional hazards regression. RESULTS: Relative to individuals who initiated treatment when SBP was 130-139 mmHg, those with pretreatment SBP ≥140 mmHg had higher ASCVD risk (hazard ratio 1.10 [95% CI 1.02, 1.19]). Relative to those with pretreatment SBP of 130-139 mmHg and on-treatment SBP of 120-129 mmHg (reference group), ASCVD incidence was higher in those with pretreatment SBP ≥140 mmHg and on-treatment SBP 120-129 mmHg (adjusted incidence rate difference [IRD] 1.0 [-0.2 to 2.1] events/1,000 person-years) and in those who achieved on-treatment SBP 130-139 mmHg (IRD 1.9 [0.6, 3.2] and 1.1 [0.04, 2.2] events/1,000 person-years for those with pretreatment SBP 130-139 mmHg and ≥140 mmHg, respectively). CONCLUSIONS: In this observational study, patients with diabetes initiating antihypertensive therapy when SBP was 130-139 mmHg and those achieving on-treatment SBP <130 mmHg had better outcomes than those with higher SBP levels when initiating or after 2 years on treatment.
OBJECTIVE: Guidelines for hypertension treatment in patients with diabetes diverge regarding the systolic blood pressure (SBP) threshold at which treatment should be initiated and treatment goal. We examined associations of early SBP treatment with atherosclerotic cardiovascular disease (ASCVD) events in U.S. adults with diabetes. RESEARCH DESIGN AND METHODS: We studied 43,986 patients with diabetes who newly initiated antihypertensive therapy between 2002 and 2007. Patients were classified into categories based on SBP at treatment initiation (130-139 or ≥140 mmHg) and after 2 years of treatment (100-119, 120-129, 130-139, 140-159, and ≥160 mmHg). The primary outcome was composite ASCVD events (fatal and nonfatal myocardial infarction and stroke), estimated using inverse probability of treatment-weighted Poisson regression and multivariable Cox proportional hazards regression. RESULTS: Relative to individuals who initiated treatment when SBP was 130-139 mmHg, those with pretreatment SBP ≥140 mmHg had higher ASCVD risk (hazard ratio 1.10 [95% CI 1.02, 1.19]). Relative to those with pretreatment SBP of 130-139 mmHg and on-treatment SBP of 120-129 mmHg (reference group), ASCVD incidence was higher in those with pretreatment SBP ≥140 mmHg and on-treatment SBP 120-129 mmHg (adjusted incidence rate difference [IRD] 1.0 [-0.2 to 2.1] events/1,000 person-years) and in those who achieved on-treatment SBP 130-139 mmHg (IRD 1.9 [0.6, 3.2] and 1.1 [0.04, 2.2] events/1,000 person-years for those with pretreatment SBP 130-139 mmHg and ≥140 mmHg, respectively). CONCLUSIONS: In this observational study, patients with diabetes initiating antihypertensive therapy when SBP was 130-139 mmHg and those achieving on-treatment SBP <130 mmHg had better outcomes than those with higher SBP levels when initiating or after 2 years on treatment.
Authors: Eric Yuk Fai Wan; Esther Yee Tak Yu; Weng Yee Chin; Colman Siu Cheung Fung; Daniel Yee Tak Fong; Edmond Pui Hang Choi; Anca Ka Chun Chan; Cindy Lo Kuen Lam Journal: Diabetes Care Date: 2018-03-28 Impact factor: 19.112
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: Rhonda M Cooper-DeHoff; Yan Gong; Eileen M Handberg; Anthony A Bavry; Scott J Denardo; George L Bakris; Carl J Pepine Journal: JAMA Date: 2010-07-07 Impact factor: 56.272
Authors: Wenhui Zhao; Peter T Katzmarzyk; Ronald Horswell; Yujie Wang; Jolene Johnson; William T Cefalu; Donna H Ryan; Gang Hu Journal: J Clin Endocrinol Metab Date: 2013-05-28 Impact factor: 5.958
Authors: Jeremy B Sussman; Eve A Kerr; Sameer D Saini; Rob G Holleman; Mandi L Klamerus; Lillian C Min; Sandeep Vijan; Timothy P Hofer Journal: JAMA Intern Med Date: 2015-12 Impact factor: 21.873
Authors: Yichi Zhang; Tianrun Cai; Sheng Yu; Kelly Cho; Chuan Hong; Jiehuan Sun; Jie Huang; Yuk-Lam Ho; Ashwin N Ananthakrishnan; Zongqi Xia; Stanley Y Shaw; Vivian Gainer; Victor Castro; Nicholas Link; Jacqueline Honerlaw; Sicong Huang; David Gagnon; Elizabeth W Karlson; Robert M Plenge; Peter Szolovits; Guergana Savova; Susanne Churchill; Christopher O'Donnell; Shawn N Murphy; J Michael Gaziano; Isaac Kohane; Tianxi Cai; Katherine P Liao Journal: Nat Protoc Date: 2019-11-20 Impact factor: 13.491
Authors: Sheng Yu; Abhishek Chakrabortty; Katherine P Liao; Tianrun Cai; Ashwin N Ananthakrishnan; Vivian S Gainer; Susanne E Churchill; Peter Szolovits; Shawn N Murphy; Isaac S Kohane; Tianxi Cai Journal: J Am Med Inform Assoc Date: 2017-04-01 Impact factor: 4.497